Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys

Journal of Nuclear Medicine

Volumn 55, Issue 10, 2014, Pages 1712-1718

  Barret, Olivier ^a   Hannestad, Jonas ^b   Alagille, David ^a   Vala, Christine ^a   Tavares, Adriana ^a   Papin, Caroline ^a   Morley, Thomas ^a   Fowles, Krista ^c   Lee, Hsiaoju ^a   Seibyl, John ^a   Tytgat, Dominique ^b   Laruelle, Marc ^b   Tamagnan, Gilles ^a  

^a Valisure   (United States)

^b UCB PHARMA   (Belgium)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A2A receptors PET imaging; Parkinson's disease; Preladenant; Receptor occupancy; Tozadenant

Indexed keywords

ADENOSINE A1 RECEPTOR; DOPAMINE; FLUORODEOXYGLUCOSE F 18; PRELADENANT; TOZADENANT; ADENOSINE A2A RECEPTOR; BENZOTHIAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG UPTAKE; FEMALE; FLOW RATE; FRONTAL CORTEX; GLOBUS PALLIDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE TRACING; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; NUCLEUS ACCUMBENS; OCCIPITAL CORTEX; PARKINSON DISEASE; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; QUANTITATIVE ANALYSIS; RECEPTOR OCCUPANCY; RHESUS MONKEY; STEADY STATE; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TEMPORAL CORTEX; VOLUME OF DISTRIBUTION; ANIMAL; BRAIN; CHEMISTRY; DISEASE MODEL; PATHOLOGY; PROCEDURES; RADIOMETRY; SCINTISCANNING; TIME; WHOLE BODY IMAGING;

ANIMALS; BENZOTHIAZOLES; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; HUMANS; MACACA MULATTA; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; RADIOMETRY; RECEPTOR, ADENOSINE A2A; TIME FACTORS; TRIAZOLES; WHOLE BODY IMAGING;

EID: 84907535626     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.142067     Document Type: Article

References (28)

1. Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34:143-151.
2. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72:432-438.
3. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol. 1989;26: 551-557.
4. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol. 2006;63:584-588.
5. Moresco RM, Todde S, Belloli S, et al. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur J Nucl Med Mol Imaging. 2005;32:405-413.
6. Hirani E, Gillies J, Karasawa A, et al. Evaluation of [4-O-methyl-11C]KW-6002 as a potential PET ligand for mapping central adenosine A2A receptors in rats. Synapse. 2001;42:164-176.
7. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 1997;27:322-335.
8. Ishiwata K, Noguchi J, Wakabayashi S, et al. 11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand. J Nucl Med. 2000;41: 345-354.
9. Sihver W, Schulze A, Wutz W, et al. Autoradiographic comparison of in vitro binding characteristics of various tritiated adenosine A2A receptor ligands in rat, mouse and pig brain and first ex vivo results. Eur J Pharmacol. 2009;616:107-114.
10. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol. 2009: 535-587.
11. Rissanen E, Virta JR, Paavilainen T, et al. Adenosine A2A receptors in secondary progressive multiple sclerosis: a [11C]TMSX brain PET study. J Cereb Blood Flow Metab. 2013;33:1394-1401.
12. Holschbach MH, Bier D, Stusgen S, et al. Synthesis and evaluation of 7-amino-2-(2(3)-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines as potential A2A adenosine receptor antagonists for positron emission tomography (PET). Eur J Med Chem. 2006;41:7-15.
13. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA. 1991;88:7238-7241.
14. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a doubleblind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008; 63:295-302.
15. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10:221-229.
16. Hauser RA, Olanow CW, Kieburtz K, et al. A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (SYN-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa [abstract]. Mov Disord. 2013;28 (suppl 1):444.
17. Dungo R, Deeks ED. Istradefylline: first global approval. Drugs. 2013;73:875-882.
18. Stone-Elander S, Thorell JO, Eriksson L, Fredholm BB, Ingvar M. In vivo biodistribution of [N-11C-methyl]KF 17837 using 3-D-PET: evaluation as a ligand for the study of adenosine A2A receptors. Nucl Med Biol. 1997;24:187-191.
19. Noguchi J, Ishiwata K, Wakabayashi S, et al. Evaluation of carbon-11-labeled KF17837: a potential CNS adenosine A2a receptor ligand. J Nucl Med. 1998;39: 498-503.
20. Bhattacharjee AK, Lang L, Jacobson O, et al. Striatal adenosine A2A receptormediated positron emission tomographic imaging in 6-hydroxydopaminelesioned rats using [18F]-MRS5425. Nucl Med Biol. 2011;38:897-906.
21. Tavares AA, Batis J, Barret O, et al. In vivo evaluation of [123I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nucl Med Biol. 2013;40:403-409.
22. Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol. 2003;30:833-844.
23. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27:1533-1539.
24. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
25. Cutler DL, Tendolkar A, Grachev ID. Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects. J Clin Pharm Ther. 2012;37:578-587.
26. Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol. 2001;28:595-608.
27. Gunn RN, Murthy V, Catafau AM, et al. Translational characterization of [11C] GSK931145, a PET ligand for the glycine transporter type 1. Synapse. 2011;65: 1319-1332.
28. Turkheimer FE, Selvaraj S, Hinz R, et al. Quantification of ligand PET studies using a reference region with a displaceable fraction: application to occupancy studies with [11C]-DASB as an example. J Cereb Blood Flow Metab. 2012;32: 70-80.